TG Therapeutics, Inc. Stock price

Equities

TGTX

US88322Q1085

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
15.21 USD -2.31% Intraday chart for TG Therapeutics, Inc. -0.26% -10.95%
Sales 2024 * 264M Sales 2025 * 413M Capitalization 2.25B
Net income 2024 * -16M Net income 2025 * 81M EV / Sales 2024 * 7.99 x
Net cash position 2024 * 146M Net cash position 2025 * 259M EV / Sales 2025 * 4.83 x
P/E ratio 2024 *
-129 x
P/E ratio 2025 *
29.6 x
Employees 264
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.9%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.31%
1 week-1.04%
Current month-11.67%
1 month+9.35%
3 months-10.79%
6 months+72.45%
Current year-10.95%
More quotes
1 week
15.03
Extreme 15.03
15.99
1 month
14.51
Extreme 14.51
19.02
Current year
12.84
Extreme 12.84
22.67
1 year
6.46
Extreme 6.46
35.67
3 years
3.48
Extreme 3.48
50.00
5 years
3.48
Extreme 3.48
56.74
10 years
3.32
Extreme 3.32
56.74
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 93-05-17
Director of Finance/CFO 42 11-12-28
Investor Relations Contact - 11-11-30
Members of the board TitleAgeSince
Chief Executive Officer 58 93-05-17
Director/Board Member 77 12-02-29
Director/Board Member 59 14-12-14
More insiders
Date Price Change Volume
24-03-28 15.21 -2.31% 2,327,786
24-03-27 15.57 +0.84% 1,454,844
24-03-26 15.44 -1.59% 2,651,466
24-03-25 15.69 +1.29% 1,770,918
24-03-22 15.49 +1.57% 2,044,626

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
15.21 USD
Average target price
29.75 USD
Spread / Average Target
+95.60%
Consensus
  1. Stock
  2. Equities
  3. Stock TG Therapeutics, Inc. - Nasdaq